Dr. Xu earned his Ph.D. from Tongji Medical College, Huazhong University of Science and Technology. He further advanced his research expertise through postdoctoral fellowships at the University of Texas MD Anderson Cancer Center and the University of Louisville School of Medicine.
Over the past five years, Dr. Xu has published a series of high-impact papers in prestigious international journals, including Cell Host & Microbe (Cover Story), Advanced Science, Small, Molecular Therapy (Cover Story), and Nature Communications. His research excellence is further demonstrated by serving as the Principal Investigator for several research projects and as a key contributor to multiple NIH-funded studies.
His current research focuses on decoding the molecular mechanisms of cellular functional remodeling within the Central Nervous System (CNS), immune cell fate determination, and neuro-immune interactions. By integrating cutting-edge multi-omics technologies with organoid models and animal systems, Dr. [Your Name] aims to explore the feasibility of targeted therapies for Alzheimer’s Disease (AD).
Dr. Xu earned his Ph.D. from Tongji Medical College, Huazhong University of Science and Technology. He further advanced his research expertise through postdoctoral fellowships at the University of Texas MD Anderson Cancer Center and the University of Louisville School of Medicine.
Over the past five years, Dr. Xu has published a series of high-impact papers in prestigious international journals, including Cell Host & Microbe (Cover Story), Advanced Science, Small, Molecular Therapy (Cover Story), and Nature Communications. His research excellence is further demonstrated by serving as the Principal Investigator for several research projects and as a key contributor to multiple NIH-funded studies.
His current research focuses on decoding the molecular mechanisms of cellular functional remodeling within the Central Nervous System (CNS), immune cell fate determination, and neuro-immune interactions. By integrating cutting-edge multi-omics technologies with organoid models and animal systems, Dr. [Your Name] aims to explore the feasibility of targeted therapies for Alzheimer’s Disease (AD).